The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial

• Main Authors: Baigent C., Landray M.J., Reith C., Emberson J., Wheeler D.C., Tomson C., Wanner C., Krane V., Cass A., Craig J., Neal B., Jiang L., Hooi L.S., Levin A., Agodoa L., Gaziano M., Kasiske B., Walker R., Massy Z.A., Feldt-Rasmussen B., Krairittichai U., Ophascharoensuk V., Fellstrom B., Holdaas H., Tesar V., Wiecek A., Grobbee D., De Zeeuw D., Gronhagen-Riska C., Dasgupta T., Lewis D., Herrington W., Mafham M., Majoni W., Wallendszus K., Grimm R., Pedersen T., Tobert J., Armitage J., Baxter A., Bray C., Chen Y., Chen Z., Hill M., Knott C., Parish S., Simpson D., Sleight P., Young A., Collins R.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-79959746706&partnerID=40&md5=f9e00a613a603cb81556e8da74bff4cf; http://cmuir.cmu.ac.th/handle/6653943832/3746
• Institution: Chiang Mai University

Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the...